Genetics Australia

genaust.com.au

Genetics Australia is a co-operative, owned by members who are shareholders. Our members are also customers who use our products and services, and benefit as a result. We are Australia’s largest artificial breeding supplier, supplying half of the genetics used by Australian dairy farmers to improve their herds.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

XYLYX BIO PARTNERS WITH INVENTIA LIFE SCIENCE TO DEVELOP TISSUE-SPECIFIC, DIGITALLY-PRINTED BIOINKS FOR DRUG DISCOVERY

Xylyx Bio, Inc. | September 02, 2021

news image

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting provides promising tools to quickly and more precisely culture cells to develop...

Read More

Industry Outlook

CULTURE BIOSCIENCES AND CYTIVA TEAM UP TO INNOVATE IN UPSTREAM BIOPROCESSING TO ADVANCE THE DEVELOPMENT AND MANUFACTURING OF NEW THERAPIES

Globenewswire | June 20, 2023

news image

Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up capabilities. Together, Cytiva and Culture Biosciences aim to bring to customers new bioprocess solutions that use digitization, in-silico approaches, and virtual monitoring and control of experiments. “Cytiva is excited to work with Culture Biosciences to help customers gain confidence that the process and...

Read More

Industry Outlook

ATTOVIA THERAPEUTICS LAUNCHES WITH $60 MILLION SERIES A FINANCING TO UNLOCK POTENTIAL OF NOVEL BIPARATOPIC NANOBODY PLATFORM

Globenewswire | June 21, 2023

news image

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a newly formed company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody™, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing led by Frazier and joined by venBio and Illumin...

Read More

SEXTON BIOTECHNOLOGIES PARTNERS WITH BIOSPHERIX TO CREATE A FULLY-ENCLOSED, MODULAR FILL-FINISH SYSTEM WITH RAPID DEPLOYMENT

Sexton Biotechnologies | June 11, 2020

news image

Sexton Biotechnologies has announced a new collaboration with BioSpherix Medical. As a tool and technologies partners of the Cell and Gene industry, Sexton and BioSpherix both recognize the need for cost-effective and flexible automation solutions during cell and gene therapy process development. While some upstream bioprocesses have been successfully automated, the final steps of downstream bioprocess, namely Fill-Finish, are often done manually with associated risks of contamination and user e...

Read More
news image

Cell and Gene Therapy

XYLYX BIO PARTNERS WITH INVENTIA LIFE SCIENCE TO DEVELOP TISSUE-SPECIFIC, DIGITALLY-PRINTED BIOINKS FOR DRUG DISCOVERY

Xylyx Bio, Inc. | September 02, 2021

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research. As researchers seek to develop more physiologically relevant in vitro models, 3D bioprinting provides promising tools to quickly and more precisely culture cells to develop...

Read More
news image

Industry Outlook

CULTURE BIOSCIENCES AND CYTIVA TEAM UP TO INNOVATE IN UPSTREAM BIOPROCESSING TO ADVANCE THE DEVELOPMENT AND MANUFACTURING OF NEW THERAPIES

Globenewswire | June 20, 2023

Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and robust scale-up capabilities. Together, Cytiva and Culture Biosciences aim to bring to customers new bioprocess solutions that use digitization, in-silico approaches, and virtual monitoring and control of experiments. “Cytiva is excited to work with Culture Biosciences to help customers gain confidence that the process and...

Read More
news image

Industry Outlook

ATTOVIA THERAPEUTICS LAUNCHES WITH $60 MILLION SERIES A FINANCING TO UNLOCK POTENTIAL OF NOVEL BIPARATOPIC NANOBODY PLATFORM

Globenewswire | June 21, 2023

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of diseases, and Frazier Life Sciences, announced the launch of Attovia Therapeutics, a newly formed company focused on creating a pipeline of biotherapeutics in immune-mediated disease and cancer. The company, based on Attobody™, Alamar’s novel proprietary biparatopic nanobody platform, concurrently closed a $60 million Series A financing led by Frazier and joined by venBio and Illumin...

Read More
news image

SEXTON BIOTECHNOLOGIES PARTNERS WITH BIOSPHERIX TO CREATE A FULLY-ENCLOSED, MODULAR FILL-FINISH SYSTEM WITH RAPID DEPLOYMENT

Sexton Biotechnologies | June 11, 2020

Sexton Biotechnologies has announced a new collaboration with BioSpherix Medical. As a tool and technologies partners of the Cell and Gene industry, Sexton and BioSpherix both recognize the need for cost-effective and flexible automation solutions during cell and gene therapy process development. While some upstream bioprocesses have been successfully automated, the final steps of downstream bioprocess, namely Fill-Finish, are often done manually with associated risks of contamination and user e...

Read More